Vyne aims to raise $88M; Sanofi in­vests in gene ther­a­py com­pa­ny; 4DMT ad­dress­es clin­i­cal hold

Plus, news about Unit­ed Ther­a­peu­tics and Mod­er­na:

Im­muno-in­flam­ma­tion biotech’s $88M: Vyne Ther­a­peu­tics an­nounced an $88 mil­lion pri­vate place­ment to, in part, help fund a Phase Ia dose-es­ca­la­tion tri­al of its BD2-se­lec­tive BET in­hibitor, VYN202. The biotech is sell­ing more than 10 mil­lion shares at Fri­day’s clos­ing price of $2.24. Vyne al­so un­veiled pre­clin­i­cal da­ta from ro­dent mod­els of VYN202 in pso­ri­a­sis and arthri­tis, in­clud­ing re­duc­tions in key dis­ease bio­mark­ers. Its stock $VYNE was up about 27% on Mon­day morn­ing. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER